Clinical Trial

Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor

Study acronym: GABRIEL
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
In this study, we want to find out more about the side effects of an investigational drug for relapsed or refractory atypical teratoid rhabdoid tumor and high-grade glioma, Gallium Maltolate (GaM) and what doses of GaM are safe for people to take. Everyone in this study will receive GaM which is still experimental and is not approved by the U.S. Food and Drug Administration. We do not know all the ways that this drug may affect people. We hope the information from this study will help us develop a better treatment for relapsed or refractory atypical teratoid rhabdoid tumor and high-grade glioma in the future.
Trial Details
NCT Number NCT07331064
Lead Sponsor Sarah Rumler
Conditions High Grade Gliomas, Atypical Teratoid Rhabdoid Tumors (ATRT), Diffuse Midline Glioma, DIPG, Diffuse Intrinsic Pontine Gliomas (DIPG)
Enrollment 15 participants
Start Date 2026-05-15
Primary Completion 2030-11-15 (estimated)
Study Completion 2031-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-09